+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Thyroid Gland Disorder Treatment Market Research and Forecast, 2019-2025

  • PDF Icon


  • April 2019
  • Region: Global
  • Orion Market Research Private Limited
  • ID: 4766762
Global Thyroid Gland Disorder Treatment Market Size, Share & Trends Analysis Report by Disorder Type (Hyperthyroidism, Hypothyroidism, and Thyroid Cancer), by Route of Administration (Oral, Parental, and Others) and Forecast, 2019-2025.

Global thyroid gland disorder treatment market is expected to register significant growth over the forecast period. The major factors that are driving the growth of the market include an increase in the prevalence of thyroid gland disorder across the globe, the rise in the number of disease awareness programs especially in the developing countries, and development of effective combination drug therapies to treat thyroid gland disorder. However, the side effects of the drugs and stringent government regulations hamper market growth. Besides, the availability of a large pool of undiagnosed patients due to the asymptomatic nature of thyroid disorders enable open new avenues for market growth during the forecast period.

Significant prevalence of thyroid cancer has been witnessed across the globe. According to the American Cancer Society, in 2019, an estimated 52,070 new cases of thyroid cancer will be registered in the US alone. Off these new cases, 37,810 and 14,260 will be diagnosed in women and men respectively. Moreover, the society also suggests that thyroid cancer will cause around 2,170 mortalities in 2019. Such prevalence of thyroid disorders such as thyroid cancer in the US will augment the demand for therapies for the treatment of thyroid gland disorders. This is expected to drive the global thyroid gland disorder treatment market over the forecast period.

Geographically, the market has been segmented into North America, Europe, Asia-Pacific, and Rest of the World. These regions contribute significantly towards the growth of the market over the forecast period. North America is expected to dominate the market share over the forecast period followed by Europe. Moreover, Asia-Pacific is expected to be the fastest growing region than any other regions across the globe. Additionally, the market consists of several players that deal with developing treatment solutions for thyroid gland disorder. Key market players are Pfizer, Inc., Abbott Laboratories, Inc., GlaxoSmithKline PLC, Macleods Pharmaceuticals Ltd., Epivax, Inc., and so on.

Research Methodology

The market study of the global thyroid gland disorder treatment market is incorporated by extensive primary and secondary research. Secondary research has been conducted to refine the available data to break down the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macroeconomic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings the authenticity of our reports.

Secondary Sources Include:
  • Financial reports of companies involved in the market

  • Whitepapers, research-papers and news blogs

  • Company websites and their product catalog

The report is intended for the service provider, research firms, investment companies, government organizations for overall market analysis and competitive analysis. The report will serve as a source for 360-degree analysis of the market thoroughly integrating different models delivering insights into the market for better business decisions.

Market Segmentation:

1. Global Thyroid Gland Disorder Management Market Research and Analysis by Disorder Type
2. Global Thyroid Gland Disorder Treatment Market Research and Analysis by Route of Administration

The Report Covers:
  • Comprehensive research methodology of the global thyroid gland disorder treatment market.

  • This report also includes a detailed and extensive market overview with key analyst insights.

  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.

  • Insights about market determinants which are stimulating the global thyroid gland disorder treatment market.

  • Detailed and extensive market segments with regional distribution of forecast revenues.

  • Extensive profiles and recent developments of market players.

Table of Contents

1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Geography
1.2.3. By Stakeholders
2. Market Overview and Insights
2.1. Definition
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
2.3. Rules &Regulations
3. Competitive Landscape
3.1. Competitive Dashboard
3.2. Key Strategy Analysis
3.3. Key Company Analysis
3.3.1. Pfizer, Inc. Overview Financial Analysis SWOT Analysis Recent Developments
3.3.2. Abbott Laboratories, Inc. Overview Financial Analysis SWOT Analysis Recent Developments
3.3.3. GlaxoSmithKline PLC Overview Financial Analysis SWOT Analysis Recent Developments
3.3.4. Merck KGaA Overview Financial Analysis SWOT Analysis Recent Developments
3.3.5. Novartis AG Overview Financial Analysis SWOT Analysis Recent Developments
4. Market Determinants
4.1. Motivators
4.2. Restraints
4.3. Opportunities
5. Market Segmentation
5.1. Global Thyroid Gland Disorder Management Market by Type
5.1.1. Hyperthyroidism
5.1.2. Hypothyroidism
5.1.3. Thyroid Cancer
5.2. Global Thyroid Gland Disorder Management Market by Route of Administration
5.2.1. Oral
5.2.2. Parenteral
5.2.3. Others
6. Regional Analysis
6.1. North America
6.1.1. United States
6.1.2. Canada
6.2. Europe
6.2.1. UK
6.2.2. Germany
6.2.3. Italy
6.2.4. Spain
6.2.5. France
6.2.6. Rest of Europe
6.3. Asia-Pacific
6.3.1. China
6.3.2. India
6.3.3. Japan
6.3.4. Rest of Asia-Pacific
6.4. Rest of the World
7. Company Profiles
7.1. Abbott Laboratories Inc.
7.2. AbbVie, Inc.
7.3. Acella Pharmaceutical LLC
7.4. Allergan PLC
7.5. Amgen, Inc.
7.6. Apitope International NV
7.7. Aspen Pharmacare Holdings Ltd.
7.8. AstraZeneca PLC
7.9. Bayer AG
7.10. Epivax, Inc.
7.11. F.Hoffman-La-Roche
7.12. Gemini Laboratories, LLC
7.13. GlaxoSmithKline PLC
7.14. IBSA Pharma Inc.
7.15. Macleods Pharmaceuticals Ltd.
7.16. Merck KGaA
7.17. Mylan NV
7.18. Novartis AG
7.19. Pfizer, Inc.
7.20. RLC Labs Inc.
7.21. Sanofi SA
7.22. Takeda Pharmaceutical Ltd.

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Abbott Laboratories Inc.

  • AbbVie, Inc.

  • Acella Pharmaceutical LLC

  • Allergan PLC

  • Amgen, Inc.

  • Apitope International NV

  • Aspen Pharmacare Holdings Ltd.

  • AstraZeneca PLC

  • Bayer AG

  • Epivax, Inc.

  • F.Hoffman-La-Roche

  • Gemini Laboratories, LLC

  • GlaxoSmithKline PLC

  • IBSA Pharma Inc.

  • Macleods Pharmaceuticals Ltd.

  • Merck KGaA

  • Mylan NV

  • Novartis AG

  • Pfizer, Inc.

  • RLC Labs Inc.

  • Sanofi SA

  • Takeda Pharmaceutical Ltd.